Generics 3

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Terbinafine manufacturers

3 products found

Filters

Filters

Filters , active

Country of origin : Egypt

Clear all

3 products found

terbinafine

Tablets 125 mg, 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Egypt
GMP approvals
Egypt
Manufacturer #21954
This pharmaceutical company, established in the Middle East, has been operating for over two decades. Their focus is on manufacturing and distributing branded generics, with a particular emphasis on providing quality medicines to the local region. They boast a significant workforce and an extensive product portfolio, including over 200 products. The company's key therapy areas include cardiovascular, gynecological, and gastrointestinal health. Their production lines include a wide range of dosage forms, such as solids, liquids, and injectables. They have obtained EU and US GMP approvals, demonstrating their commitment to high-quality manufacturing standards. Their products are distributed across various markets, including the Middle East, and they are actively expanding their presence in international markets.

Manufacturer usually replies in 1 days

Want to see all 3 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Terbinafine is an antifungal medication pityriasis versicolor, fungal nail infections, tinea capitis, tinea corporis, tinea cruris, tinea pedis, and cutaneous candidiasis. Terbinafine manufacturers produce medications with it as the standalone ingredient, as well as use it in combination drug formulations along with ingredients such as mometasone and urea. Suppliers of terbinafine market it in the form of 125mg and 250mg oral tablets as well as 10mg/g topical creams. The developer and earliest manufacturer of terbinafine was Novartis, who first introduced it into the market under the trade name Lamisil in Europe in 1991, and the U.S. in 1996. Lamisil is currently available in over 70 countries worldwide, including but not limited to Australia, Brazil, Russia, South Africa, Thailand, and many more geographical markets. What is more, following the expiry of the manufacturer’s patent in 2007, other producers and suppliers launched their formulations of the drug into the market. Terbinafine is included in the World Health Organization’s list of Essential Medicines that contains the most important medications recommended for a basic health system. And it is a widely prescribed drug, with over 1 million prescriptions being registered yearly in the U.S. alone. The global terbinafine market is fragmented, with multiple pharmaceutical companies, from small local manufacturers to large multinational industry players marketing both generic and trade name terbinafine formulations. Among the largest manufacturers and suppliers of terbinafine are well-known names such as Novartis, GlaxoSmithKline, Gedeon Richter, Sun Pharmaceuticals, Teva, Pfizer, and Mylan. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified terbinafine manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. Costs per 28 (250mg) tablets of terbinafine range from 25 EUR to 30 EUR, whereas 15g (10mg/g) of terbinafine topical cream can cost anywhere from 4,00 EUR to 11,00 EUR.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation